Company intelligence / Profile preview

Akshaya Bio

Edmonton, Alberta, Canada

Ownership: Private
Development stage: Other

Overview

Akshaya Bio’s Chimigen technology enables the creation of a new class of therapeutic vaccines and agents targeting both infectious diseases and cancer. The platform mimics natural immune processes and claims improved antigen presentation and safety (no adjuvant required). Product pipeline includes candidates for hepatitis B and C, HIV, influenza, malaria, cancer, TB, and Ebola, but clinical results have not been published.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineBiologicAntibody
Industry: Biotech

Beyond the preview

Go deeper on Akshaya Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akshaya Bio.

Explore the full profile